Genetic polymorphisms in the three Malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 1, 2011, Pages 185-191

  Hassan, Bassam Abdul Rasool ^a   Yusoff, Zuraidah Binti Mohd ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

Acute and delayed nausea and vomiting; CYP3A4; Genetic polymorphisms; Granisetron

Indexed keywords

EID: 79958708406     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Aapro M (2004). Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist, 9, 673-80.
2. Bernard S, Neville KA, Nguyen AT, et al (2006). Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist, 11, 126-35.
3. Bloechl-Daum B, Deuson RR, Mavros P, et al (2006). Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol, 24, 4472-8.
4. Booth CM, Clemons M, Dranitsaris G, et al (2007). Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol, 5, 374-80.
5. Cohen L, De Moor CA, Eisenberg P, et al (2007). Chemotherapyinduced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings. Support Care Cancer, 15, 497-503.
6. Dempsey CL, Coop AJ, Shillington A, et al (2010). Antiemetic effectiveness of ondansetron and granisetron in: results. In: http://www.medscape.com/viewarticle/475180_3, ed. (Accessed 2010).
7. Dupont WD, Plummer WD (2004) PS: Power and Sample Size Calculation IN BIOSTATISTICS, V. (ed. Power sample size). 2.1.31 ed. Nashville, Vanderbilt Biostatistics (Accessed 2004).
8. Fumoleau P, Bonneterre J, Luporsi E (2003). Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today? J Clin Oncol, 21, 1190-2.
9. Gross SA, Bridge S, Shenfield GM (1999). Pharmacokinetic of tolbutamide in ethnic Chinese. J Clin Pharmacol, 47, 151-6.
10. Hesketh PJ (2005). Management of nausea and vomiting in cancer treatment: introduction, scope of the problem. In: Hesketh PJ, ed. Management of nausea and vomiting in cancer and cancer treatment. Jones and Bartlett, Mississauga, 1-14.
11. Hsieh KP, Lin YY, Cheng CL, et al (2001). Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos, 29, 268-73.
12. Huang P, Zhu B, Wang LS, et al (2003). Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women. Eur J Clin Pharmacol, 59, 471-6.
13. Kaur G, Rosli Ismail Lee, Suk Kam, et al (2007). Assessment of correlation between clinicopathological features and lymph node metastases in breast cancer. Internet J Pathol, 5, 1528-8307.
14. Kaiser R, Sezer O, Papies A, et al (2002). Patient-tailored antiemetic treatment with 5-Hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol, 20, 2805-11.
15. Mokhlis S (2009). Malaysian Chinese consumers: their ethnic attitudes and shopping orientations. Int J Business and Management Services, 4, 53-62.
16. Molassiotis A, Mok TS, Yam BM, et al (2002). An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy. Eur J Cancer Care, 11, 108-13.
17. Naing KNJ, Azillah AAN, Nooriny I, et al (2010). Anxiety and depressive symptoms and coping strategies in nasopharyngeal carcinoma patients in hospital Kuala Lumpur. Malaysian J Med Hlth Sci, 6, 71-81.
18. National Cancer Registry of Malaysia (2003). Second report of the national cancer registry cancer incidence in Malaysia 2003. In: Malaysia, Ministry of Health (ed., National Cancer Registry) (Accessed 2003).
19. Rais N, Chawla YK, Kohli KK (2006). CYP3A phenotypes and genotypes in north Indians. Eur J Clin Pharmacol, 62, 417-22.
20. Ruzilawati AB, Mohd Suhaimi AW, Gan SH (2007). Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clin Chim Acta, 383, 158-62.
21. Rubenstein E (2005). The role of prognostic factors in chemotherapy induced nausea and vomiting. In: Hesketh PJ, ed. Management of Nausea and Vomiting in Cancer and Cancer Treatment. Jones and Bartlett Publishers, Mississauga, 87-98.
22. Verrill M (2009). Chemotherapy for early-stage breast cancer: a brief history. Br J Cancer, 101, 2-5.
23. Yang YS, Wong LP, Lee TC, et al (2004). Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol, 58, 332-5.
24. Yi-Fan Z, Xiao-Yan C, Da-Fang Z, et al (2003). Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. Acta Pharmacol Sin, 24, 715-8.
25. Wikipedia the Free Encyclopedia (2010). Han Chinese. In: Wikipedia the Free Encyclopedia, ed. Wikipedia the free encyclopedia. (Accessed 2010).